Keros Therapeutics, Inc. KROS
- rinvatercept — Duchenne Muscular Dystrophy Phase 2
- elritercept — Myelodysplastic Syndromes Phase 3
- elritercept — Myelofibrosis Phase 3
- rinvatercept — Amyotrophic Lateral Sclerosis Phase 1
Home › Targets › TGF-β ligands
TGF-β ligands (1 companies · 4 programs)
Companies with an active program directed at TGF-β ligands.